GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (STU:ADY) » Definitions » Piotroski F-Score

Amedisys (STU:ADY) Piotroski F-Score : 4 (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Amedisys Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amedisys has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Amedisys's Piotroski F-Score or its related term are showing as below:

STU:ADY' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Amedisys was 8. The lowest was 2. And the median was 6.


Amedisys Piotroski F-Score Historical Data

The historical data trend for Amedisys's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Piotroski F-Score Chart

Amedisys Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 5.00 6.00 4.00

Amedisys Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 5.00 4.00 4.00

Competitive Comparison of Amedisys's Piotroski F-Score

For the Medical Care Facilities subindustry, Amedisys's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amedisys's Piotroski F-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Amedisys's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Amedisys's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -74.094 + 24.325 + 17.718 + 13.248 = €-19 Mil.
Cash Flow from Operations was 56.081 + -9.223 + 55.305 + -6.018 = €96 Mil.
Revenue was 510.389 + 521.194 + 523.413 + 525.701 = €2,081 Mil.
Gross Profit was 235.838 + 229.199 + 228.674 + 229.887 = €924 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(1818.46 + 1829.757 + 1899.69 + 1889.176 + 1922.681) / 5 = €1871.9528 Mil.
Total Assets at the begining of this year (Mar23) was €1,818 Mil.
Long-Term Debt & Capital Lease Obligation was €385 Mil.
Total Current Assets was €484 Mil.
Total Current Liabilities was €446 Mil.
Net Income was 27.982 + 25.898 + 29.941 + 23.58 = €107 Mil.

Revenue was 527.764 + 563.568 + 530.588 + 519.667 = €2,142 Mil.
Gross Profit was 228.628 + 238.119 + 231.183 + 225.448 = €923 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(1732.82 + 1892.933 + 2001.948 + 1865.575 + 1818.46) / 5 = €1862.3472 Mil.
Total Assets at the begining of last year (Mar22) was €1,733 Mil.
Long-Term Debt & Capital Lease Obligation was €404 Mil.
Total Current Assets was €379 Mil.
Total Current Liabilities was €330 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amedisys's current Net Income (TTM) was -19. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amedisys's current Cash Flow from Operations (TTM) was 96. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-18.803/1818.46
=-0.01034007

ROA (Last Year)=Net Income/Total Assets (Mar22)
=107.401/1732.82
=0.06198047

Amedisys's return on assets of this year was -0.01034007. Amedisys's return on assets of last year was 0.06198047. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Amedisys's current Net Income (TTM) was -19. Amedisys's current Cash Flow from Operations (TTM) was 96. ==> 96 > -19 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=384.836/1871.9528
=0.20557997

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=404.448/1862.3472
=0.21717111

Amedisys's gearing of this year was 0.20557997. Amedisys's gearing of last year was 0.21717111. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=484.332/446.071
=1.08577334

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=378.79/329.749
=1.14872221

Amedisys's current ratio of this year was 1.08577334. Amedisys's current ratio of last year was 1.14872221. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Amedisys's number of shares in issue this year was 32.979. Amedisys's number of shares in issue last year was 32.643. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=923.598/2080.697
=0.44388875

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=923.378/2141.587
=0.4311653

Amedisys's gross margin of this year was 0.44388875. Amedisys's gross margin of last year was 0.4311653. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=2080.697/1818.46
=1.14420829

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=2141.587/1732.82
=1.23589698

Amedisys's asset turnover of this year was 1.14420829. Amedisys's asset turnover of last year was 1.23589698. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amedisys has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Amedisys  (STU:ADY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Amedisys Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Amedisys's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Amedisys (STU:ADY) Business Description

Traded in Other Exchanges
Address
3854 American Way, Suite A, Baton Rouge, LA, USA, 70816
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Amedisys (STU:ADY) Headlines

No Headlines